171 results
8-K
EX-10.1
2bgg1 z959cw5
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
EX-23.1
en4jxvxi493y sb
30 Nov 23
Registration of securities for employees
4:16pm
8-K
fy6b1t5w36sm 47
14 Nov 23
Other Events
12:00am
8-K
EX-23.1
0iot5c5u9tqmljdav3
14 Nov 23
Other Events
12:00am
8-K
EX-99.1
k8alypdtg90
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
qe8rz396
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K/A
EX-23.1
2zzx7bl
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K/A
eyy1ql3p3
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
w2tfl 6yvyh
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.2
mpq9jm6gjlkxvp8m
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
mdgq12t81ktm yblnkh2
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
h33hl zgv
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
daddp9zn
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm